Pneumonia vaccine remains expensive after 10 years of Gavi’s AMC funding
NewsFebruary 16, 2018
When the innovative USD 1.5 billion financing mechanism, the AMC, was launched by Gavi ten years ago, it was expected to do two things: accelerate the distribution of pneumonia vaccine among children in poor countries and incentivise more suppliers to enter the market, thereby increasing competition and pushing prices down. The AMC succeeded on the first but failed on the second.
The rest of the content is only available for subscribers.